RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

Poster session.

Presentations:

• 9:00 AM – 11:00 AM ET

  Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis
  William H. Robinson, MD, PhD – Stanford University
• 9:00 AM – 11:00 AM ET

  Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations with Disease Characteristics, Body Composition, and Physical Functioning
  Patrick Gould, BA – University of Pennsylvania
• 9:00 AM – 11:00 AM ET

  Development of Functional Assays to Pre-qualify Human Mesenchymal Stem Cells for Rheumatoid Arthritis Treatment
  Maya Breitman, PhD – MetroHealth Medical Center,Case Western Reserve University School of Medicine
• 9:00 AM – 11:00 AM ET

  HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
  Qiong Wu, PhD – Vanderbilt University Medical Center
• 9:00 AM – 11:00 AM ET

  WITHDRAWN
• 9:00 AM – 11:00 AM ET

  Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis
  Andreas Kerschbaumer, MD – Medical University of Vienna
• 9:00 AM – 11:00 AM ET

  Locating Cellular Subsets in Rheumatoid Arthritis Synovium Using CO-Detection by IndEXing (CODEX)
  Gary Firestein, MD – University of California - San Diego
• 9:00 AM – 11:00 AM ET

  Nuclei Detection in Rheumatoid Arthritis Synovial Tissue Using Artificial Intelligence
  Steven Guan, -None- – MITRE
• 9:00 AM – 11:00 AM ET

  Serum Interferon-Alpha Levels Could Help Identify a Subgroup of Rheumatoid Arthritis with Poorer Physical Function and Higher Physician Global Assessment
  Yong Gil Hwang, MD – University of Pittsburgh Physicians
• 9:00 AM – 11:00 AM ET

  Serum Proteomics Implicates Neutrophil Degranulation in Rheumatoid Arthritis Disease Activity
  Liam O'Neil, MD, MHS – University of Manitoba
• 9:00 AM – 11:00 AM ET

  Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort
  Stéphanie de Montjoye – Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC)
• 9:00 AM – 11:00 AM ET

  The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs
  Takayoshi Owada, MD, PhD – Dokkyo Medical University Saitama Medical Center
• 9:00 AM – 11:00 AM ET

  Exploring the Significance of Anti-Nuclear Antibody Positivity in the Medical Management of Patients with Rheumatoid Arthritis
  Sujaytha Paknikar, BS – Mayo Clinic Alix School of Medicine
• 9:00 AM – 11:00 AM ET

  Increased Risk of Hospitalization in Patients with RA Who Are ACPA Positive and Shared Epitope Positive
  Nancy Shadick, MD, MPH – Brigham & Women's Hospital
• 9:00 AM – 11:00 AM ET

  Sunlight Exposure, Sun-protective Behaviour, and Anti-citrullinated Protein Antibody Positivity: A General Population-based Study in Quebec, Canada
  Sasha Bernatsky, MD, PhD – McGill University
• 9:00 AM – 11:00 AM ET

  Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
  Dana Wiens, BSc – University of Manitoba
• 9:00 AM – 11:00 AM ET

  Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Development in a Population at Risk for Rheumatoid Arthritis
  Yogan Kisten, BSc, MMed – Karolinska Institute, Department of Medicine, Rheumatology Division and early arthritis clinic of the Karolinska University Hospital
• 9:00 AM – 11:00 AM ET

  X-rays Bone Erosions Are Uncommon in Anti-CCP Positive Individuals At-risk of Rheumatoid Arthritis with Musculoskeletal Symptoms Without Clinical Synovitis, and Do Not Predict the Development of Inflammatory Arthritis
  Andrea Di Matteo, MD, PhD – Leeds Institute of Rheumatic and Musculoskeletal Medicine
• 9:00 AM – 11:00 AM ET

  Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Risk of Progression to Rheumatoid Arthritis
  Nora Petrovská, MD – Institute of Rheumatology, Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
• 9:00 AM – 11:00 AM ET

  Anti-Protein-Arginine Deiminase (PAD) 1 IgG Is a Promising Novel Autoantigen in Rheumatoid Arthritis (RA) and Increases Diagnostic Performance in Combination with Anti-PAD4 IgG Using a Composite Biomarker Score
  Marcos Lopez-Hoyos – Marques de Valdecilla University Hospital-IDIVAL
• 9:00 AM – 11:00 AM ET

  Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
  Klara Prajzlerova, -None- – Institute of Rheumatology
• 9:00 AM – 11:00 AM ET

  Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data
  Dmitry Rychkov, PhD – Bakar Computational Health Sciences Institute
• 9:00 AM – 11:00 AM ET

  High Disease Activity at Baseline and Seropositivity Are Associated with Treatment Response at One Year Post Synovial Biopsy in RA Patients
  Kieran Murray, MD, -None- – Saint Vincent's University Hospital
• 9:00 AM – 11:00 AM ET

  ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
  Rodrigo Garcia Salinas, MD – Hospital Italiano de La Plata